Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Current concepts of pathogenesis, microbiology, diagnosis, and management of infections of the fetus and newborn are reviewed in this chapter with the goal of providing a brief synthesis and overview. Information within this chapter regarding specific infections or syndromes is illustrative only. Detailed discussions are provided in the subsequent sections, to which the reader should refer to gain the more comprehensive knowledge needed to properly evaluate and manage these conditions.
The first section of the book contains chapters providing the global perspective on fetal and neonatal infections as well as chapters addressing obstetric factors, immunity, host defenses, and the role of human breast milk in fetal and neonatal infections. Chapters containing detailed information about specific bacterial, viral, protozoan, helminthic, and fungal infections follow in subsequent sections. The final section contains chapters addressing nosocomial infections, the diagnosis and therapy of infections in the fetus and neonate, and prevention of fetal and neonatal infections through immunization of the mother or neonate.
Important changes continue to occur in the epidemiology, diagnosis, prevention, and management of infectious diseases of the fetus and newborn infant since publication of the last edition of this book. Some of these changes are noted in Table 1-1 and are discussed in this and the relevant chapters.
Epidemiology | Increased viability of very-low-birth-weight infants at risk for invasive infectious diseases Increased number of multiple births (often of very low birth weight) because of successful techniques for management of infertility Global perspective of vertically transmitted infectious diseases Global decline in infant mortality but lesser decline of neonatal mortality |
Diagnosis | Polymerase chain reaction assay for diagnosis of infection in mother, fetus, and neonate Relative decrease in use of fetal blood and chorionic villus sampling and increase in use of amniotic fluid sampling for diagnosis of fetal infectious diseases |
Prevention | Intrapartum antibiotic prophylaxis widely implemented to prevent early-onset group B streptococcal infection Antiretroviral therapy in pregnancy and postpartum to prevent transmission of HIV to fetus |
Treatment | Spread within nurseries of multiple antibiotic-resistant bacterial pathogens Increased use of vancomycin for β-lactam–resistant gram-positive infections Increased use of acyclovir for infants with suspected herpes simplex infection Use of ganciclovir or valganciclovir for overtly symptomatic congenital CMV |
To keep pace with these changes, with the eighth edition, the editors have sought to streamline the references while maintaining full citation formats both in the print and online editions. All chapters have been updated through extensive revisions, and in some cases, new chapters have been prepared by different authors to provide a fresh viewpoint on certain key topics. There is no longer a separate chapter devoted to smallpox, information about which is now incorporated into Chapter 30 (Less Common Viral Infections). Conversely, with the resurgence of pertussis cases in the United States and elsewhere, a new Chapter 21 on pertussis has been prepared by James Cherry.
Substantial progress has been made toward reducing the burden of infectious diseases in the fetus and newborn infant. The incidence of early-onset group B streptococcal (GBS) disease has been reduced by aggressive use of intrapartum chemoprophylaxis, in particular, as guided by the culture-based screening strategy now recommended for universal use in the United States and several other countries. Vertical transmission of human immunodeficiency virus (HIV) has been reduced by identification of the infected mother and subsequent treatment, including broader recommendations for the use of antiretroviral regimens among pregnant and postpartum women that are practical in countries with high prevalence but limited resources.
There has been a substantial commitment of resources by government agencies and philanthropies, such as the Bill and Melinda Gates Foundation, the Clinton Health Access Initiative, and Save the Children, among others, to combat global infectious diseases in mothers and children. Global mortality for children younger than 5 years fell by 41% between 1990 and 2011 from a rate of 87 to 51 deaths per 1000 live births, but still totals 6.9 million deaths per year globally. Neonatal mortality has not declined as quickly and now constitutes 40% of total under-5-years mortality, and great disparities remain; the global neonatal mortality rates in 2011 in the United States and European regions are 6.1 and 13 per 1000 live births, respectively, but in the African region the rate is 106 per 1000 live births ( www.who.int/gho/child_health/mortality/mortality_under_five_text/en/index.html ). Stillbirths, defined as late fetal deaths at greater than 1000 g or greater than 28 weeks of gestation, are estimated at 3 million cases annually, with 99% occurring in low- and middle-income countries. Whereas infection accounts for approximately one third of neonatal deaths globally, it accounts for a considerably smaller fraction in the United States.
Setbacks facing initiatives to reduce the global burden of infectious disease in the fetus and newborn infant include the continuing epidemic of HIV infection in sub-Saharan Africa, particularly among women, and the lack of finances to provide effective treatment for these women and their newborn infants. In the United States, infectious disease challenges include the increase in antimicrobial resistance among nosocomial pathogens and in the incidence of invasive fungal infections among infants of extremely low birth weight. Moreover, the rate of pertussis is rising, notably so in older children and adolescents in the United States and other countries, with disproportional impact on morbidity and mortality of the newborn. This rising prevalence is likely due, in part, to accelerated waning of immunity associated with the use of acellular vaccines, which have supplanted the killed whole-cell vaccine primarily in high-resource settings.
Use of the Internet continues to expand rapidly, allowing access to information hitherto unavailable to physicians or parents. Physicians may obtain current information about diseases and management as well as various guidelines for diagnosis and treatment. Interested parents who have access to the Internet can explore various websites that present a vast array of information but, unfortunately, also misinformation. As an example of the latter, a case of neonatal tetanus was associated with the use of cosmetic facial clay (Indian Healing Clay) as a dressing on an umbilical cord stump. The product had been publicized as a healing salve by midwives on an Internet site dedicated to “cordcare.” The antivaccination movement is active on the Internet, deploying a variety of tactics and rhetoric to effectively spread their messages. Because much of the information on the Internet is from commercial sources and parties with varying interests and expertise, physicians should be prepared to assist interested parents and patients in finding Internet sites of genuine value. Several Internet sites pertinent to infectious diseases of the fetus and newborn infant are listed in Table 1-2 .
Agency for Healthcare Research and Quality | http://www.ahrq.gov |
American Academy of Pediatrics | http://www.aap.org |
American College of Obstetricians and Gynecologists | http://www.acog.org |
Centers for Disease Control and Prevention | http://www.cdc.gov |
Food and Drug Administration | http://www.fda.gov |
Immunization Action Coalition | http://www.immunize.org |
Information on AIDS Trials | http://www.aidsinfo.nih.gov |
March of Dimes | http://www.marchofdimes.com |
Morbidity and Mortality Weekly Report | http://www.cdc.gov/mmwr |
National Center for Health Statistics | http://www.cdc.gov/nchs |
Pediatric Infectious Diseases Society | http://www.pids.org |
General academic information | http://www.googlescholar.com ; http://www.ncbi.nlm.nih.gov/pubmed |
Vital statistics relevant to infectious disease risk in neonates in the United States for 2010 to 2011 are listed in Table 1-3 . The disparities in birth weight, prenatal care, and neonatal mortality among different racial and ethnic groups in the United States are important to note and to consider in the context of the global disparities noted above.
Racial/Ethnic Origin of Mother | ||||||||
---|---|---|---|---|---|---|---|---|
All Races | Non-Hispanic White | Non-Hispanic Black | Hispanic | |||||
2010 | 1990 | 2010 | 1990 | 2010 | 1990 | 2010 | 1990 | |
Mother | ||||||||
<20 years old | 9.3 | 12.8 | 6.7 | 9.6 | 15.2 | 23.2 | 13.1 | 16.8 |
≥40 years old | 2.9 | 1.2 | 3.0 | 1.2 | 2.3 | 0.8 | 2.4 | 1.2 |
Diabetes during pregnancy | 5.1 | 2.1 | 4.7 | 2.2 | 4.5 | 1.8 | 5.2 | 2.0 |
Cesarean delivery | 32.8 | 22.7 | 32.6 | 23.4 | 35.5 | 22.1 | 31.8 | 21.2 |
Infant | ||||||||
Birth weight † | ||||||||
LBW | 8.2 | 7.0 | 7.1 | 5.6 | 13.5 | 13.3 | 7.0 | 6.1 |
VLBW | 1.5 | 1.3 | 1.2 | 0.9 | 3.0 | 2.9 | 1.2 | 1.0 |
Gestational age ‡ | ||||||||
Preterm | 12.0 | 10.6 | 10.8 | 8.5 | 17.1 | 18.9 | 11.8 | 11.0 |
Preterm early | 3.5 | 3.3 | 2.9 | 2.4 | 6.1 | 7.4 | 3.3 | 3.2 |
Preterm late | 8.5 | 7.3 | 7.8 | 6.1 | 11.0 | 11.5 | 8.5 | 7.8 |
∗ All values are in percent births.
† LBW , low birth weight (<2500 g); VLBW , very low birth weight (<1500 g).
‡ Preterm early: <34 weeks of gestation; late preterm: 34-36 weeks of gestation.
The number of infectious diseases in fetuses and newborn infants must be extrapolated from selected studies (see chapters on specific diseases). Approximately 1% of newborn infants shed cytomegalovirus (CMV), greater than 4% of infants are born to mothers infected with Chlamydia trachomatis, and bacterial sepsis develops in 1 to 4 infants per 1000 live births. Since the institution of intrapartum chemoprophylaxis in the United States, the number of infants with early-onset GBS disease has declined, with reduction in incidence from approximately 1.5 cases to 0.29 case per 1000 live births. In the United States, the use of maternal highly active antiretroviral treatment and peripartum chemoprophylaxis reduced the rate of mother-to-child transmission of HIV from approximately 25% of infants born to mothers who received no treatment to less than 2%; less complex but practical regimens of intrapartum prophylaxis have helped to reduce the rate of perinatal HIV transmission in the developing world. Recently revised World Health Organization (WHO) guidelines ( www.who.int/hiv/pub/guidelines/arv2013/intro/rag/en/index2.html ) now also recommend that all HIV-infected pregnant and breastfeeding women and HIV-infected partners of monogamous HIV-uninfected pregnant women receive highly active antiretroviral treatment regardless of their CD4 T-cell numbers, which should help to further lower the rates of HIV transmission in resource-limited settings. Among sexually transmitted diseases, the rate of congenital syphilis had declined substantially in the United States to 13.4 per 100,000 live births in 2000 ; however, after 14 years of decline, the rate of congenital syphilis increased in 2006 and 2007 from 9.3 to 10.5 cases per 100,000 live births, in parallel with the increase in the syphilis rates among the general population. Immunization has virtually eliminated congenital rubella syndrome in newborn infants of U.S.-born mothers, but cases continue to occur in infants of foreign-born mothers; the mothers of 24 of 26 infants with congenital rubella born between 1997 and 1999 were foreign born, 21 of them Hispanic. Efforts led by the Pan American Health Organization to eliminate congenital rubella syndrome in the Americas by 2010 appears to have been successful, with the last case reported in 2009, providing impetus for a global attack on the problem through universal immunization.
Consequences of perinatal infections vary depending on whether the infection occurs in utero or during the intrapartum or postpartum periods. Infection acquired in utero can result in resorption of the embryo, abortion, stillbirth, malformation, intrauterine growth restriction, prematurity, or the untoward sequelae of chronic postnatal infection. Infection acquired during the intrapartum or early postpartum period may result in severe systemic disease that leads to death or the establishment of persistent postnatal infection. In utero infection and intrapartum infections may lead to late-onset disease. Such infections may not be apparent at birth but may manifest with signs or symptoms weeks, months, or years later, as exemplified by chorioretinitis of Toxoplasma gondii infection, hearing loss of rubella, and immunologic defects that result from HIV infection. The immediate and the long-term effects of these infections constitute a major problem throughout the world.
Pregnant women are not only exposed to infections prevalent in the community but are also likely to reside with young children or to associate with groups of young children, which represents a significant additional factor in exposure to infectious agents. Most infections in pregnant women affect the upper respiratory and gastrointestinal tracts, and either resolve spontaneously without therapy or are readily treated with antimicrobial agents. Such infections usually remain localized and have no effect on the developing fetus. The infecting organism may invade the bloodstream, however, and subsequently infect the placenta and fetus.
Successful pregnancy is a unique example of immunologic tolerance—the mother must be tolerant of her allogeneic fetus (and vice versa). The basis for maternal-fetal tolerance is not completely understood but is known to reflect local modifications of host defenses at the maternal-fetal interface and more global changes in immunologic competence in the mother. Specific factors acting locally in the placenta include indoleamine 2,3-dioxygenase, which suppresses cell-mediated immunity by catabolizing the essential amino acid tryptophan, and regulatory proteins that prevent complement activation. Based on data from murine models, there is an accumulating body of evidence that pregnancy is associated with maternal-fetal tolerance that depends in part on the development of maternal regulatory T-cell–mediated tolerance to fetal antigens inherited from the father. Regulatory T cells are also relatively more abundant and active in the human fetus, whose T-cell populations are also otherwise naïve in phenotype and function (see Chapter 4 ). Further, as pregnancy progresses, a general shift from T-helper type 1 (Th1) cell-mediated immunity to T-helper type 2 (Th2) responses also occurs in the mother. Nonetheless, because Th1 cell-mediated immunity is important in host defense against intracellular pathogens, the reduced Th1 bias established during normal gestation may compromise successful immunity against organisms such as T. gondii . In addition, it has been proposed that a strong curative Th1 response against an organism may overcome protective T-regulatory and Th2 activity at the maternal-fetal interface, resulting in fetal loss.
Transplacental spread and invasion of the bloodstream after maternal infection is the usual route by which the fetus becomes infected. Uncommonly, the fetus may be infected by extension of infection in adjacent maternal tissues and organs, including the peritoneum and the genitalia, during parturition, or as a result of invasive methods for the diagnosis and therapy of fetal disorders, such as the use of monitors, chorionic villus biopsy, sampling of fetal blood, and intrauterine transfusion.
Microorganisms of concern are listed in Table 1-4 and include those identified in the acronym TORCH : T. gondii, rubella virus, CMV, and herpes simplex virus (HSV). As a point of historical interest, the O in TORCH originally stood for “other infections/pathogens,” reflecting an early appreciation of this possibility. A new acronym is needed to include other, well-described causes of in utero infection: syphilis, enteroviruses, varicella-zoster virus (VZV), HIV, Lyme disease (Borrelia burgdorferi), and parvovirus. In certain geographic areas, Plasmodium and Trypanosoma cruzi are responsible for in utero infections. TORCHES CLAP (see Table 1-4 ) is an inclusive acronym. Case reports indicate other organisms that are unusual causes of infections transmitted by a pregnant woman to her fetus, including Brucella melitensis , Coxiella burnetii (Q fever), Babesia microti (babesiosis), human T-cell lymphotropic virus (HTLV) types 1 and 2 (although the main route of transmission of these viruses is through breastfeeding), hepatitis G and TT viruses, human herpesvirus 6, and dengue.
TO | Toxoplasma gondii |
R | Rubella virus |
C | Cytomegalovirus |
H | Herpes simplex virus |
E | Enteroviruses |
S | Syphilis ( Treponema pallidum ) |
C | Chickenpox (varicella-zoster virus) |
L | Lyme disease ( Borrelia burgdorferi ) |
A | AIDS (HIV) |
P | Parvovirus B19 |
Among these other organisms, investigators from France reported that Coxiella burnetti (the causative agent of the zoonotic disease Q fever) infection of the pregnant woman is associated with untoward pregnancy outcomes, including spontaneous abortion, intrauterine fetal demise, preterm delivery, and intrauterine growth retardation in a large majority (81%) of untreated women. Restricting their analysis to women in whom such complications were not evident at presentation, complications were observed in 14 of 21 women who were not treated and 7 of 16 who received long-term (>5 weeks) daily cotrimoxazole therapy ( P = .047). They acknowledge the noncontrolled nature of their data and the possible selection bias but nonetheless propose that such therapy be given to all pregnant women with proven Coxiella burnetti infection. However, other, though smaller, reports have not observed a high rate of complications and would restrict such therapy to women with symptomatic acute infection or chronic Q fever.
Before rupture of fetal membranes, organisms in the genital tract may invade the amniotic fluid and infect the fetus. These organisms can invade the placenta through microscopic defects in the membranes, particularly in devitalized areas overlying the cervical os. It also is possible that microorganisms gain access to the fetus from descending infection through the fallopian tubes in women with salpingitis or peritonitis, or from direct extension of an infection in the uterus, such as myometrial abscess or cellulitis. Available evidence does not suggest, however, that transtubal or transmyometrial passage of microbial agents is a significant route of fetal infection.
Invasive techniques developed for in utero diagnosis and therapy are potential sources of infection for the fetus. Abscesses have been observed in infants who had scalp punctures for fetal blood sampling or electrocardiographic electrodes attached to their scalps. Cases of osteomyelitis of the skull and streptococcal sepsis have followed local infection at the site of a fetal monitoring electrode ; HSV infections at the fetal scalp electrode site also have been reported. Intrauterine transfusion for severe erythroblastosis diagnosed in utero also has resulted in infection of the fetus. In one case, CMV infection reportedly resulted from intrauterine transfusion ; in another instance, contamination of donor blood with a gram-negative coccobacillus, Acinetobacter calcoaceticus, led to an acute placentitis and subsequent fetal bacteremia.
Fetal infection in the absence of rupture of internal membranes usually occurs transplacentally after invasion of the maternal bloodstream. Microorganisms in the blood may be carried within white blood cells or attached to erythrocytes, or they may be present in serum independent of cellular elements.
The potential consequences of invasion of the mother’s bloodstream by microorganisms or their products ( Fig. 1-1 ) include placental infection without infection of the fetus, fetal infection without infection of the placenta, absence of fetal and placental infection, and infection of placenta and fetus (see Chapter 3 for additional discussion of this topic).
After reaching the intervillous spaces on the maternal side of the placenta, organisms can remain localized in the placenta without affecting the fetus. Evidence that placentitis can occur independently of fetal involvement has been shown for maternal tuberculosis, syphilis, malaria, coccidioidomycosis, CMV, rubella virus, and mumps vaccine virus infection. The reasons for the lack of spread to the fetus after placental infection are unknown. Defenses of the fetus that may operate after placental infection include the villous trophoblast, placental macrophages, and locally produced immune factors, such as antibodies and cytokines.
Microorganisms may traverse the chorionic villi directly through pinocytosis, placental leaks, or diapedesis of infected maternal leukocytes and erythrocytes. Careful histologic studies usually reveal areas of placentitis sufficient to serve as a source of fetal infection, however.
Invasion of the bloodstream by microorganisms is common in pregnant women, yet in most cases, neither fetal nor placental infection results. Bacteremia may accompany abscesses, cellulitis, bacterial pneumonia, pyelonephritis, appendicitis, endocarditis, or other pyogenic infections; nevertheless, placental or fetal infection as a consequence is rare. In most cases, the fetus is likely protected through efficient clearance of microbes by maternal innate or preexisting adaptive immunity.
Many bacterial diseases of the pregnant woman, including typhoid fever, pneumonia, gram-negative bacterial sepsis, and urinary tract infections, may affect the developing fetus without direct microbial invasion of the placenta or fetal tissues. Similarly, protozoan infection in the mother, such as malaria, and systemic viral infections, including varicella, variola, and measles, also may affect the fetus indirectly. Fever, anoxia, circulating toxins, or metabolic and hematologic derangements in the mother concomitant with these infections can affect the pregnancy, possibly resulting in abortion, stillbirth, or premature delivery.
The effects of microbial toxins on the developing fetus are uncertain. The fetus may be adversely affected by toxic shock in the mother secondary to Staphylococcus aureus or Streptococcus pyogenes infection. Botulism in pregnant women has not been associated with disease in infants. A unique case of Guillain-Barré syndrome in mother and child shows that infection-induced, antibody-mediated autoimmune disease in the mother may be transmitted to her infant. In this case, the disease was diagnosed in the mother during week 29 of pregnancy. A healthy infant was delivered vaginally at 38 weeks of gestation, while the mother was quadriplegic and on respiratory support. On day 12 of life, the infant developed flaccid paralysis of all limbs with absence of deep tendon reflexes, and cerebrospinal fluid (CSF) examination revealed increased protein concentration without white blood cells. The delay in onset of paralysis in the infant seemed to reflect transplacentally transferred blocking antibodies specifically directed at epitopes of the mature, but not the fetal, neuromuscular junction. The infant improved after administration of intravenous immunoglobulin.
The association of maternal urinary tract infection with premature delivery and low birth weight is a well-studied example of a maternal infection that adversely affects growth and development of the fetus, despite no evidence of fetal or placental infection. Asymptomatic bacteriuria in pregnancy has been linked to increased low-birth-weight deliveries. A meta-analysis of interventional studies concluded that antibiotic treatment is effective in reducing the risk of pyelonephritis in pregnancy and the risk for preterm delivery, although the evidence supporting this latter conclusion is not as strong. The basis for the premature delivery and low birth weight of infants of mothers with bacteriuria remains obscure and may, in part, reflect an altered maternal genital tract microbiome and dysbiosis-associated preterm labor (see Chapter 3 ).
Microorganisms disseminate from the infected placenta to the fetal bloodstream through infected emboli of necrotic chorionic tissues or through direct extension of placental infection to the fetal membranes, with secondary amniotic fluid infection and aspiration by the fetus.
Hematogenous transplacental spread may result in death and resorption of the embryo, abortion and stillbirth of the fetus, and live birth of a premature or term infant who may or may not be healthy. The effects of fetal infection may appear in a live-born infant as low birth weight (resulting from intrauterine growth restriction), developmental anomalies, congenital disease, or none of these. Infection acquired in utero may persist after birth and cause significant abnormalities in growth and development that may be apparent soon after birth or may not be recognized for months or years. The variability of the effects of fetal infection is emphasized by reports of biovular twin pregnancies that produced one severely damaged infant and one infant with minimal or no detectable abnormalities.
Various organisms may infect the pregnant woman in the first few weeks of gestation and cause death and resorption of the embryo. Because loss of the embryo usually occurs before the woman realizes she is pregnant or seeks medical attention, it is difficult to estimate the incidence of this outcome for any single infectious agent. The incidence of early pregnancy loss after implantation from all causes has been estimated to be 31%. The proportion of cases of loss because of infection is unknown.
The earliest recognizable effects of fetal infection are seen after 6 to 8 weeks of pregnancy and include abortion and stillbirth. Intrauterine death may result from overwhelming fetal infection, or the microorganisms may interfere with organogenesis to such an extent that the development of functions necessary for continued viability is interrupted. The precise mechanisms responsible for early spontaneous termination of pregnancy are unknown; in many cases, it is difficult to ascertain whether fetal death caused or resulted from the expulsion of the fetus.
Numerous modifying factors probably determine the ultimate consequence of intrauterine infection, including virulence or tissue tropism of the microorganisms, stage of pregnancy, associated placental damage, and severity of the maternal illness. Primary infection is likely to have a more important effect on the fetus than recurrent infection. Recurrent maternal CMV infection is less severe than primary infection and is significantly less likely to result in congenital CMV infection of the fetus. Available studies do not distinguish between the direct effect of the microorganisms on the developing fetus and the possibility of an indirect effect attributable to illness or poor health of the mother.
Prematurity is defined as the birth of a viable infant before week 37 of gestation. Premature birth may result from almost any agent capable of establishing fetal infection during the last trimester of pregnancy. Many microorganisms commonly responsible for prematurity are also implicated as significant causes of stillbirth and abortion ( Table 1-5 ).
Disease | |||||
---|---|---|---|---|---|
Organism | Prematurity | Intrauterine Growth Restriction/Low Birth Weight | Developmental Anomalies | Congenital Disease | Persistent Postnatal Infection |
Viruses | CMV HSV Rubeola Smallpox HBV HIV ∗ |
CMV Rubella VZV ∗ HIV ∗ |
CMV Rubella VZV Coxsackievirus B ∗ HIV ∗ |
CMV Rubella VZV HSV Mumps ∗ Rubeola Vaccinia Smallpox Coxsackievirus B Poliovirus HBV HIV LCV Parvovirus |
CMV Rubella VZV HSV HBV HIV |
Bacteria | Treponema pallidum Mycobacterium tuberculosis Listeria monocytogenes Campylobacter fetus Salmonella typhi |
T. pallidum M. tuberculosis L. monocytogenes C. fetus S. typhi Borrelia burgdorferi |
T. pallidum M. tuberculosis |
||
Protozoa | Toxoplasma gondii Plasmodium ∗ Trypanosoma cruzi |
T. gondii Plasmodium T. cruzi |
T. gondii Plasmodium T. cruzi |
T. gondii Plasmodium |
∗ Association of effect with infection has been suggested and is under consideration.
Previous studies have shown that women in premature labor with bacteria-positive amniotic fluid cultures have elevated amniotic fluid levels of multiple proinflammatory cytokines. In many patients with elevated levels of interleukin-6 (IL-6), results of amniotic fluid culture were negative. Premature births are invariably observed, however, in women in premature labor having positive amniotic fluid culture and elevated amniotic fluid levels of IL-6. To clarify further the role of elevated levels of IL-6 in amniotic fluid, Hitti and colleagues amplified bacterial DNA encoding 16S ribosomal RNA (rRNA) by using a polymerase chain reaction (PCR) assay to detect infection in amniotic fluid of women in premature labor whose membranes were intact. In patients who were culture-negative, PCR assay detected bacterial infection in a significant percentage of those with elevated IL-6 levels. These data suggest that 33% of women in premature labor with culture-negative amniotic fluid but with elevated IL-6 levels may have infected amniotic fluid. The investigators concluded that the association between infected amniotic fluid and premature labor may be underestimated on the basis of amniotic fluid cultures and that a broad-spectrum bacterial 16S rDNA PCR assay may be useful for detecting prenatal infection. The utility of amniotic fluid testing for IL-6 and other biomarkers in predicting risk for preterm birth is discussed further in Chapter 3 .
In recent years, many studies have explored how abnormal composition of the vaginal flora, maternal vaginal colonization with Ureaplasma or Mycoplasma spp., or development of bacterial vaginosis (BV) during pregnancy can influence the risk of preterm birth. Meta-analyses of recent interventional studies of antibiotic administration to correct such dysbiosis during the first trimester are, to date, inconclusive with respect to reducing preterm birth. Further advances in the detection of microbes and the assessment of microbial diversity through high-throughput, next-generation sequencing–based assessment offer the promise to better understand the role of microbes in preterm labor and its untoward consequences (see Chapter 3 ).
Infection of the fetus may result in birth of an infant who is small for gestational age. Although many maternal infections are associated with low-birth-weight infants and infants who are small for gestational age, causal evidence is sufficient only for congenital rubella, VZV infection, toxoplasmosis, and CMV infection, although it is likely that congenital syphilis can, in some cases, also result in intrauterine growth restriction (see Chapter 16 ).
The organs of infants dying with congenital rubella syndrome or congenital CMV infection contain reduced numbers of morphologically normal cells. By contrast, in infants who are small for gestational age with growth deficit from noninfectious causes, such as maternal toxemia or placental abnormalities, the parenchymal cells are normal in number but have a reduced amount of cytoplasm, presumably because of fetal malnutrition.
CMV, rubella virus, and VZV cause developmental anomalies in the human fetus. Coxsackieviruses B3 and B4 have been associated with congenital heart disease. Although the pathogenetic mechanisms responsible for fetal abnormalities produced by most infectious agents remain obscure, histologic studies of abortuses and congenitally infected infants have suggested that some viruses render these effects through mediating cell death, alterations in cell growth, or chromosomal damage. Inflammation and tissue destruction, rather than teratogenic activity, seem to be responsible for the widespread structural abnormalities characteristic of congenital syphilis, transplacental HSV and VZV infection, and toxoplasmosis. Infants with congenital toxoplasmosis may have microcephaly, hydrocephalus, or microphthalmia, but these manifestations usually result from an intense necrotizing process involving numerous organisms and are more appropriately defined as lesions of congenital infection, rather than as effects of teratogenic activity of the organism.
Some mycoplasmas and viruses produce chromosomal damage in circulating human lymphocytes or in human cells in tissue culture. The relationship of these genetic aberrations to the production of congenital abnormalities in the fetus is unknown.
Clinical evidence of intrauterine infections, resulting from tissue damage or secondary physiologic changes caused by the invading organisms, may be present at birth or may manifest soon thereafter or years later. The clinical manifestations of infection acquired in utero or at delivery in the newborn infant are summarized in Table 1-6 . Signs of widely disseminated infection may be evident during the neonatal period in infants with congenital rubella; toxoplasmosis; syphilis; or congenital CMV, HSV, or enterovirus infection. These signs include jaundice, hepatosplenomegaly, and pneumonia, each of which reflects lesions caused by microbial invasion and proliferation, rather than by defects in organogenesis. Although these signs of congenital infection are not detected until the neonatal period, the pathologic processes responsible for their occurrence have been progressing for weeks or months before delivery. In some infants, the constellation of signs is sufficient to suggest the likely congenital infection ( Table 1-7 ). In other infants, the signs are transient and self-limited and resolve as neonatal defense mechanisms control the spread of the microbial agent and tissue destruction. If damage is severe and widespread at the time of delivery, survival of the infant is unlikely.
Rubella Virus | Cytomegalovirus | Toxoplasma gondii | Herpes Simplex Virus | Treponema pallidum | Enteroviruses |
---|---|---|---|---|---|
Hepatosplenomegaly Jaundice Pneumonitis Petechiae or purpura Meningoencephalitis Hydrocephalus Adenopathy Hearing deficits Myocarditis Congenital defects ∗ Bone lesions ∗ Glaucoma ∗ Chorioretinitis or retinopathy ∗ Cataracts ∗ Microphthalmia |
Hepatosplenomegaly Jaundice Pneumonitis Petechiae or purpura Meningoencephalitis Hydrocephalus Microcephaly ∗ Intracranial calcifications ∗ Hearing deficits Chorioretinitis or retinopathy Optic atrophy |
Hepatosplenomegaly Jaundice Pneumonitis Petechiae or purpura Meningoencephalitis Hydrocephalus ∗ Microcephaly Maculopapular exanthems Intracranial calcifications ∗ Myocarditis Bone lesions Chorioretinitis or retinopathy ∗ Cataracts Optic atrophy Microphthalmia Uveitis |
Hepatosplenomegaly Jaundice Pneumonitis Petechiae or purpura Meningoencephalitis Hydrocephalus Microcephaly Maculopapular exanthems Vesicles ∗ Myocarditis Chorioretinitis or retinopathy Cataracts Conjunctivitis or keratoconjunctivitis ∗ |
Hepatosplenomegaly Jaundice Pneumonitis Petechiae or purpura Meningoencephalitis Adenopathy Maculopapular exanthems ∗ Bone lesions ∗ Glaucoma Chorioretinitis or retinopathy Uveitis |
Hepatosplenomegaly Jaundice Pneumonitis Petechiae or purpura Meningoencephalitis Adenopathy Maculopapular exanthems Paralysis ∗ Myocarditis ∗ Conjunctivitis or keratoconjunctivitis |
Microorganism | Signs |
---|---|
Toxoplasma gondii | Hydrocephalus, diffuse intracranial calcification, chorioretinitis |
Rubella virus | Cardiac defects, sensorineural hearing loss, cataracts, microcephaly, “blueberry muffin” skin lesions, hepatomegaly, interstitial pneumonitis, myocarditis, disturbances in bone growth, intrauterine growth restriction |
CMV | Microcephaly, periventricular calcifications, jaundice, petechiae or purpura, hepatosplenomegaly, intrauterine growth restriction |
HSV | Skin vesicles or scarring, eye scarring, microcephaly or hydranencephaly, vesicular skin rash, keratoconjunctivitis, meningoencephalitis, sepsis with hepatic failure |
Treponema pallidum | Bullous, macular, or eczematous skin lesions involving palms and soles; rhinorrhea; dactylitis and other signs of osteochondritis and periostitis; hepatosplenomegaly; lymphadenopathy |
VZV | Limb hypoplasia, cicatricial skin lesions, ocular abnormalities, cortical atrophy |
Parvovirus B19 | Nonimmune hydrops fetalis |
HIV | Severe thrush, failure to thrive, recurrent bacterial infections, calcification of basal ganglia |
It is frequently difficult to determine whether an infection in the newborn infant was acquired in utero, intrapartum, or postpartum. If the onset of clinical signs after birth occurs within the minimal incubation period for the disease (e.g., 3 days for enteroviruses, 10 days for VZV and rubella viruses), it is likely that the infection was acquired before delivery. The interval between malaria exposure in the mother and congenital malaria in the infant can be prolonged; one case of congenital malaria resulting from Plasmodium malariae occurred in an infant born in the United States 25 years after the mother had emigrated from China. Children with perinatal HIV infection can be diagnosed by 6 months of age using a DNA (or RNA) PCR method, which has largely replaced other approaches for viral detection. A variable fraction (less than half) of children with perinatal HIV contract the infection in utero, depending on the setting and maternal treatment. Virus-negative infants who later become virus-positive may have been infected in the intrapartum or early postpartum period, including via breastfeeding, especially when neither the infant nor the mother is receiving antiretroviral prophylaxis while breastfeeding. In this situation, up to a 54% increase in postpartum HIV transmission associated with breastfeeding has been documented.
Most newborn infants infected in utero by rubella virus, T. gondii, CMV, HIV, or Treponema pallidum have no signs of congenital disease. Fetal infection by a limited inoculum of organisms or with a strain of low virulence or pathologic potential may underlie this low incidence of clinical disease in infected infants. Alternatively, gestational age may be the most important factor in determining the ultimate consequences of prenatal infection. When congenital rubella and toxoplasmosis are acquired during the last trimester of pregnancy, the incidence of clinical disease in the infected infants is lower than when microbial invasion occurs during the first or second trimester. Congenital syphilis most commonly results from exposure during the second or third trimesters but can be transmitted to the fetus in the first trimester.
Absence of clinically apparent disease in the newborn may be misleading. Careful observation of infected but healthy-appearing children over months or years often reveals defects that were not apparent at birth. The failure to recognize such defects early in life may be due to the inability to test young infants for the sensory and developmental functions involved. Hearing defects identified years after birth may be the only manifestation of congenital rubella. Significant sensorineural deafness and other central nervous system deficiencies have affected children with congenital CMV infection who were considered to be normal during the neonatal period. In utero infection with Toxoplasma, rubella, and CMV may have manifestations that are difficult to recognize, including failure to thrive, visual defects, and minimal-to-severe brain dysfunction, including motor, learning, language, and behavioral disorders. Infants infected with HIV are usually asymptomatic at birth and for the first few months of life. The median age of onset for signs of congenital HIV infection is approximately 3 years, but many children remain asymptomatic for more than 5 years. Signs of perinatal infection related to HIV include failure to thrive, persistent diarrhea, recurrent suppurative infections, and diseases associated with opportunistic infections that occur weeks to months or years after birth. Of particular concern is a report by Wilson and colleagues showing stigmata of congenital T. gondii infection, including chorioretinitis and blindness, in almost all of 24 children at follow-up evaluations; the children had serologic evidence of infection but were without apparent signs of disease at birth and either did not receive treatment or received inadequate treatment.
Because abnormalities may become obvious only as the child develops and fails to reach appropriate physiologic or developmental milestones, it is crucial to perform careful and thorough follow-up examinations in infants born to women with known or suspected infections during pregnancy.
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here